A prospective clinical study of neoadjuvant chemotherapy with sindilizumab for locally advanced gastric cancer
Latest Information Update: 16 Jul 2022
At a glance
- Drugs Sintilimab (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 07 Jun 2022 Results (n=30 )presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 31 Mar 2022 New trial record
- 14 Mar 2022 Results (n=30) of an analysis assessing the systemic immune-inflammatory index (SII) combined with prognostic nutritional index (PNI) score to predict the efficacy of anti-programmed death 1 antibody sintilimab and XELOX regimen (capecitabine plus oxaliplatin) in the treatment of locally advanced gastric cancerpublished in the BMC Gastroenterology